• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form S-8 filed by Personalis Inc.

    8/5/25 5:07:41 PM ET
    $PSNL
    Medical Specialities
    Health Care
    Get the next $PSNL alert in real time by email
    S-8 1 d39299ds8.htm S-8 S-8

    As filed with the Securities and Exchange Commission on August 5, 2025

    Registration No. 333-   

     

     
     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    FORM S-8

    REGISTRATION STATEMENT

    UNDER

    THE SECURITIES ACT OF 1933

     

     

    PERSONALIS, INC.

    (Exact name of registrant as specified in its charter)

     

     

     

    Delaware   27-5411038

    (State or other jurisdiction of

    Incorporation or organization)

     

    (I.R.S. Employer

    Identification No.)

    6600 Dumbarton Circle

    Fremont, California 94555

    (650) 752-1300

    (Address of principal executive offices) (Zip code)

    2020 Inducement Plan

    (Full titles of the plans)

     

     

    Christopher Hall

    President and Chief Executive Officer

    Personalis, Inc.

    6600 Dumbarton Circle

    Fremont, California 94555

    (650) 752-1300

    (Name and address of agent for service) (Telephone number, including area code, of agent for service)

    Copies to:

     

    Laura Berezin

    Asa Henin

    Allison Peth

    Cooley LLP

    1700 Seventh Avenue

    Seattle, WA 98101-1355

    (206) 452-8700

     

     

    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

     

    Large accelerated filer   ☐    Accelerated filer   ☐
    Non-accelerated filer   ☒    Smaller reporting company   ☒
         Emerging growth company   ☐

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐

     

     
     


    REGISTRATION OF ADDITIONAL SHARES PURSUANT TO GENERAL INSTRUCTION E

    This Registration Statement on Form S-8 is being filed by Personalis, Inc. (the “Registrant”) to register 350,000 additional shares of the Registrant’s common stock, par value $0.0001 per share (“Common Stock”), reserved for issuance under the Company’s 2020 Inducement Plan.

    Pursuant to General Instruction E of Form S-8, the contents of the Registration Statement on Form S-8 filed with the Securities and Exchange Commission (the “Commission”) on May 7, 2020 (File No.  333-238080) and the Registration Statement on Form S-8 filed with the Commission on May 15, 2023 (File No. 333-271940) are hereby incorporated in this Registration Statement by reference to the extent not replaced hereby.

    PART II

    INFORMATION REQUIRED IN THE REGISTRATION STATEMENT

    Item 3. Incorporation of Documents by Reference.

    The following documents filed by the Registrant with the Commission are incorporated by reference into this Registration Statement:

    (a) The Registrant’s Annual Report on Form 10-K for the fiscal year ended December 31, 2024, filed with the Commission on February 27, 2025, including the information specifically incorporated by reference into the Annual Report from the Registrant’s Definitive Proxy Statement for the 2025 Annual Meeting of Stockholders, as filed with the Commission on April 3, 2025.

    (b) The Registrant’s Quarterly Reports on Form 10-Q for the fiscal quarter ended March 31, 2025, filed with the Commission on May 6, 2025, and for the fiscal quarter ended June 30, 2025, filed with the Commission on August 5, 2025.

    (c) The Registrant’s Current Reports on Form 8-K filed with the Commission on May  19, 2025 and July 9, 2025.

    (d) The description of the Registrant’s Common Stock filed as Exhibit 4.1 which is contained in a registration statement on Form 8-A filed on June 17, 2019 (File No. 001-38943) under the Exchange Act, including any amendment or report filed for the purpose of updating such description, including Exhibit 4.1 to the Registrant’s Annual Report on Form 10-K for the year ended December 31, 2020 filed with the Commission on February 25, 2021.

    (e) All other reports and documents subsequently filed by the Registrant pursuant to Sections 13(a), 13(c), 14 and 15(d) of the Exchange Act (other than Current Reports furnished under Item 2.02 or Item 7.01 of Form 8-K and exhibits furnished on such form that relate to such items and other portions of documents that are furnished but not filed or are otherwise not incorporated into registration statements pursuant to the applicable rules promulgated by the Commission) on or after the date of this Registration Statement and prior to the filing of a post-effective amendment to this Registration Statement which indicates that all securities offered have been sold or which deregisters all securities then remaining unsold, shall be deemed to be incorporated by reference herein and to be a part of this Registration Statement from the date of the filing of such reports and documents. Any statement contained in a document incorporated or deemed to be incorporated by reference herein shall be deemed to be modified or superseded for purposes of this Registration Statement to the extent that a statement contained herein or in any subsequently filed document that also is deemed to be incorporated by reference herein modifies or supersedes such statement. Any such statement so modified or superseded shall not be deemed, except as so modified or superseded, to constitute a part of this Registration Statement.

     

    1.


    Item 8. Exhibits.

     

        

    Incorporation by Reference

    Exhibit
    Number
      

    Description

      

    Form

       File No.    Exhibit    Filing Date
     4.1    Amended and Restated Certificate of Incorporation of Personalis, Inc.    8-K    001-38943    3.1    6/24/2019
     4.2    Amended and Restated Bylaws of Personalis, Inc.    8-K    001-38943    3.1    10/31/2022
     4.3    Form of common stock certificate of the Registrant.    S-1/A    333-231703    4.1    6/7/2019
     5.1*    Opinion of Cooley LLP.            
    23.1*    Consent of BDO USA, P.C. Independent Registered Public Accounting Firm.            
    23.2*    Consent of Cooley LLP (reference is made to Exhibit 5.1).            
    24.1*    Power of Attorney (reference is made to the signature page hereto).            
    99.1*    Personalis, Inc. 2020 Inducement Plan, as amended            
    99.2    Form of RSU Award Agreement under 2020 Inducement Plan.    10-K    001-38943    10.5    2/28/2024
    99.3    Form of Option Agreement under 2020 Inducement Plan.    10-K    001-38943    10.6    2/28/2024
    107*    Filing Fee Table            
     
    *

    Filed herewith.

     

    2


    SIGNATURES

    Pursuant to the requirements of the Securities Act of 1933, as amended, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Fremont, State of California, on August 5, 2025.

     

    PERSONALIS, INC.
    By:   /s/ Aaron Tachibana
      Aaron Tachibana
      Chief Financial Officer and Chief Operating Officer
      (Principal Financial and Accounting Officer)

    POWER OF ATTORNEY

    KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints Christopher Hall and Aaron Tachibana as his or her true and lawful attorneys-in-fact and agents, with the full power of substitution, for him or her and in their name, place or stead, in any and all capacities, to sign any and all amendments to this Registration Statement (including post-effective amendments), and to file the same, with all exhibits thereto and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorney-in-fact and agent full power and authority to do and perform each and every act and thing requisite and necessary to be done in connection therewith, as fully to all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that said attorney-in-fact and agent, or his substitute or substitutes, may lawfully do or cause to be done by virtue hereof.

    Pursuant to the requirements of the Securities Act of 1933, as amended, this Registration Statement on Form S-8 has been signed by the following persons in the capacities and on the dates indicated.

     

    Name and Signature

      

    Title

     

    Date

    /s/ Christopher Hall

       President, Chief Executive Officer and Director   August 5, 2025
    Christopher Hall    (Principal Executive Officer)  

    /s/ Aaron Tachibana

       Chief Financial Officer and Chief Operating Officer   August 5, 2025
    Aaron Tachibana    (Principal Financial and Accounting Officer)  

    /s/ Karin Eastham

       Director   August 5, 2025
    Karin Eastham     

    /s/ Olivia Bloom

       Director   August 5, 2025
    Olivia Bloom     

    /s/ A. Blaine Bowman

       Director   August 5, 2025
    A. Blaine Bowman     

    /s/ Woodrow A. Myers, Jr.

       Director   August 5, 2025
    Woodrow A. Myers, Jr., M.D.     

    /s/ Lonnie Shoff

       Director   August 5, 2025
    Lonnie Shoff     

    /s/ Kenneth Widder

       Director   August 5, 2025
    Kenneth J. Widder, M.D.     

     

    3

    Get the next $PSNL alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $PSNL

    DatePrice TargetRatingAnalyst
    5/15/2025$6.00Buy
    Guggenheim
    3/17/2025$8.00Buy
    Canaccord Genuity
    2/6/2023$8.00Hold → Buy
    Needham
    2/6/2023Hold → Buy
    Needham
    2/25/2022$30.00 → $24.00Outperform
    Oppenheimer
    2/25/2022$30.00 → $18.00Buy
    Citigroup
    2/25/2022$50.00 → $38.00Buy
    HC Wainwright & Co.
    1/7/2022$27.00 → $23.00Neutral → Buy
    BofA Securities
    More analyst ratings

    $PSNL
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Personalis Reports Second Quarter 2025 Financial Results

    Strong Q2 Clinical Momentum with 59% Sequential Growth in Test Volume Personalis, Inc. (NASDAQ:PSNL), a leader in advanced genomics for precision oncology, today reported financial results for the second quarter ended June 30, 2025, and recent accomplishments of its "Win-in-MRD" strategy: Second Quarter 2025 and Recent Business Highlights Clinical Adoption Acceleration: Delivered 3,478 clinical tests in the second quarter, a 59% sequential increase over Q1 2025, demonstrating accelerating physician adoption of the NeXT Personal® platform Commercial Partnership Expansion: Broadened the strategic collaboration with Tempus AI, Inc. (Tempus) to add colorectal cancer, a major new indic

    8/5/25 4:01:00 PM ET
    $PSNL
    Medical Specialities
    Health Care

    Personalis to Announce Second Quarter 2025 Financial Results

    Personalis, Inc. (NASDAQ:PSNL), a leader in advanced genomics for cancer, announced today that it will release its second quarter 2025 financial results on Tuesday, August 5, 2025. In conjunction with the release, Personalis will host a conference call and webcast that day at 2:00 p.m. Pacific Time / 5:00 p.m. Eastern Time to discuss its financial results and recent highlights. Interested parties may access the call by dialing 877-451-6152 for domestic callers or 201-389-0879 for international callers. The webinar of the call may be accessed by visiting the Events section of the company's website at investors.personalis.com. A replay of the webinar will be available shortly after the conc

    7/22/25 4:01:00 PM ET
    $PSNL
    Medical Specialities
    Health Care

    Personalis Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    Personalis, Inc. (NASDAQ:PSNL), a leader in advanced genomics for precision oncology, today announced that the Compensation Committee of its Board of Directors granted, on July 15, 2025, a non-qualified stock option to purchase an aggregate of 100,000 shares of its common stock to Personalis' new Vice President, Corporate Controller under Personalis' 2020 Inducement Plan. The 2020 Inducement Plan is used exclusively for the grant of equity awards to individuals who were not previously an employee, or non-employee director, of Personalis, as an inducement material to such individual's entering into employment with Personalis, pursuant to Rule 5635(c)(4) of the Nasdaq Listing Rules. Persona

    7/18/25 4:00:00 PM ET
    $PSNL
    Medical Specialities
    Health Care

    $PSNL
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Myers Woodrow A Jr bought $16,700 worth of shares (10,000 units at $1.67), increasing direct ownership by 62% to 26,116 units (SEC Form 4)

    4 - Personalis, Inc. (0001527753) (Issuer)

    3/5/24 5:15:53 PM ET
    $PSNL
    Medical Specialities
    Health Care

    $PSNL
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    CFO AND COO Tachibana Aaron sold $4,211 worth of shares (641 units at $6.57), decreasing direct ownership by 0.39% to 164,458 units (SEC Form 4)

    4 - Personalis, Inc. (0001527753) (Issuer)

    7/30/25 4:20:06 PM ET
    $PSNL
    Medical Specialities
    Health Care

    CHIEF MEDICAL OFFICER AND EVP Chen Richard sold $2,970 worth of shares (452 units at $6.57), decreasing direct ownership by 0.36% to 124,505 units (SEC Form 4)

    4 - Personalis, Inc. (0001527753) (Issuer)

    7/30/25 4:20:09 PM ET
    $PSNL
    Medical Specialities
    Health Care

    CFO AND COO Tachibana Aaron sold $6,390 worth of shares (1,291 units at $4.95), decreasing direct ownership by 0.78% to 165,099 units (SEC Form 4)

    4 - Personalis, Inc. (0001527753) (Issuer)

    5/20/25 5:53:11 PM ET
    $PSNL
    Medical Specialities
    Health Care

    $PSNL
    SEC Filings

    View All

    SEC Form S-8 filed by Personalis Inc.

    S-8 - Personalis, Inc. (0001527753) (Filer)

    8/5/25 5:07:41 PM ET
    $PSNL
    Medical Specialities
    Health Care

    SEC Form 8-K filed by Personalis Inc.

    8-K - Personalis, Inc. (0001527753) (Filer)

    8/5/25 4:38:05 PM ET
    $PSNL
    Medical Specialities
    Health Care

    SEC Form 10-Q filed by Personalis Inc.

    10-Q - Personalis, Inc. (0001527753) (Filer)

    8/5/25 4:05:49 PM ET
    $PSNL
    Medical Specialities
    Health Care

    $PSNL
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Guggenheim initiated coverage on Personalis with a new price target

    Guggenheim initiated coverage of Personalis with a rating of Buy and set a new price target of $6.00

    5/15/25 8:13:23 AM ET
    $PSNL
    Medical Specialities
    Health Care

    Canaccord Genuity initiated coverage on Personalis with a new price target

    Canaccord Genuity initiated coverage of Personalis with a rating of Buy and set a new price target of $8.00

    3/17/25 8:20:27 AM ET
    $PSNL
    Medical Specialities
    Health Care

    Personalis upgraded by Needham with a new price target

    Needham upgraded Personalis from Hold to Buy and set a new price target of $8.00

    2/6/23 9:09:41 AM ET
    $PSNL
    Medical Specialities
    Health Care

    $PSNL
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Personalis Inc.

    SC 13G/A - Personalis, Inc. (0001527753) (Subject)

    8/19/24 6:03:38 AM ET
    $PSNL
    Medical Specialities
    Health Care

    SEC Form SC 13G filed by Personalis Inc.

    SC 13G - Personalis, Inc. (0001527753) (Subject)

    7/26/24 12:56:21 PM ET
    $PSNL
    Medical Specialities
    Health Care

    Amendment: SEC Form SC 13D/A filed by Personalis Inc.

    SC 13D/A - Personalis, Inc. (0001527753) (Subject)

    6/28/24 4:01:17 PM ET
    $PSNL
    Medical Specialities
    Health Care

    $PSNL
    Leadership Updates

    Live Leadership Updates

    View All

    Personalis Appoints Former Roche Diagnostics and GRAIL Executive Deepshikha Bhandari as SVP, Regulatory, Quality and Clinical Compliance

    Bhandari to drive regulatory strategies for minimal residual disease (MRD) cancer test Personalis achieves ISO 13485:2016 certification, attesting to its ability to deliver medical devices and related services of the highest quality Personalis, Inc. (NASDAQ:PSNL), a leader in advanced genomic testing for precision oncology, today announced the appointment of Deepshikha Bhandari as SVP, Regulatory, Quality and Clinical Compliance. With over two decades of industry marketing and regulatory affairs experience, Ms. Bhandari will help the company navigate the regulatory requirements for the NeXT Personal® MRD test. She was most recently VP, Regulatory Affairs at GRAIL, and previously held se

    10/18/23 7:15:00 AM ET
    $PSNL
    Medical Specialities
    Health Care

    Dr. Kenneth J. Widder Joins Personalis Board of Directors

    Personalis, Inc. (NASDAQ:PSNL) today announced that it has appointed Kenneth J. Widder, M.D., to its Board of Directors. Dr. Widder currently serves on the boards of QuidelOrtho Corporation and Evoke Pharma, Inc. and has over 40 years of experience working with biomedical companies, having previously served as a founder, director and/or CEO of Sydnexis, Inc., OrphoMed, Inc., Sytera, Inc., NovaCardia, Inc., Santarus, Inc., and Molecular Biosystems Inc., and as a general partner at LVP Life Science Ventures (formerly Latterell Venture Partners) and Windamere Venture Partners. He holds an M.D. from Northwestern University and trained in pathology at Duke University. "We are delighted to ha

    6/13/23 7:01:00 PM ET
    $PSNL
    Medical Specialities
    Health Care

    Personalis Announces CEO Retirement and Transition

    Personalis, Inc. (NASDAQ:PSNL), a leader in advanced genomics for precision oncology, today announced that John West, co-founder, CEO and member of the board of directors of Personalis, notified the Company of his decision to retire as CEO and a director at the end of the calendar year. Mr. West has served in the DNA sequencing field for over forty years, and co-founded Personalis with four Stanford professors in 2011. Effective December 31, 2022, Aaron Tachibana, Personalis Chief Financial Officer, will serve as interim CEO and Christopher Hall, Personalis SVP and Head, Diagnostics Business, will be promoted to President. Mr. West will continue to serve as an advisor to the Board. "We th

    12/14/22 4:02:00 PM ET
    $PSNL
    Medical Specialities
    Health Care

    $PSNL
    Financials

    Live finance-specific insights

    View All

    Personalis Reports Second Quarter 2025 Financial Results

    Strong Q2 Clinical Momentum with 59% Sequential Growth in Test Volume Personalis, Inc. (NASDAQ:PSNL), a leader in advanced genomics for precision oncology, today reported financial results for the second quarter ended June 30, 2025, and recent accomplishments of its "Win-in-MRD" strategy: Second Quarter 2025 and Recent Business Highlights Clinical Adoption Acceleration: Delivered 3,478 clinical tests in the second quarter, a 59% sequential increase over Q1 2025, demonstrating accelerating physician adoption of the NeXT Personal® platform Commercial Partnership Expansion: Broadened the strategic collaboration with Tempus AI, Inc. (Tempus) to add colorectal cancer, a major new indic

    8/5/25 4:01:00 PM ET
    $PSNL
    Medical Specialities
    Health Care

    Personalis to Announce Second Quarter 2025 Financial Results

    Personalis, Inc. (NASDAQ:PSNL), a leader in advanced genomics for cancer, announced today that it will release its second quarter 2025 financial results on Tuesday, August 5, 2025. In conjunction with the release, Personalis will host a conference call and webcast that day at 2:00 p.m. Pacific Time / 5:00 p.m. Eastern Time to discuss its financial results and recent highlights. Interested parties may access the call by dialing 877-451-6152 for domestic callers or 201-389-0879 for international callers. The webinar of the call may be accessed by visiting the Events section of the company's website at investors.personalis.com. A replay of the webinar will be available shortly after the conc

    7/22/25 4:01:00 PM ET
    $PSNL
    Medical Specialities
    Health Care

    Personalis Reports First Quarter 2025 Financial Results

    Clinical test volume of 2,184 increased 52% sequentially Pharma tests and services of $13.6 million increased 39% year-over-year Personalis, Inc. (NASDAQ:PSNL), a leader in advanced genomics for precision oncology, today reported financial results for the first quarter of 2025 ended March 31, 2025, and provided recent business highlights. Recent Business Highlights Delivered 2,184 total molecular tests in the first quarter of 2025, an increase of 52%, compared with 1,441 tests delivered in the fourth quarter of 2024, signifying increasing adoption of Personalis' technology Highlighted compelling performance of NeXT Personal for resectable Stage I-IV colorectal cancer (CRC) in a study

    5/6/25 4:01:00 PM ET
    $PSNL
    Medical Specialities
    Health Care